Faculty Awards 2021: Kenneth Sherman
UC College of Medicine doctor honored with Distinguished Research Professor Award (STEMM)
Kenneth Sherman, MD, PhD, is enjoying a successful career in medicine because of his ability to marry his desire for exemplary patient care with a need to stay at the forefront of cutting-edge research that advances our knowledge of the digestive tract. He’s both a basic scientist with a doctoral degree in microbiology and a physician with a medical degree trained primarily as a hepatologist. Currently, the director of the UC Division of Digestive Diseases, Sherman has spent nearly four decades focusing on ailments of the liver.
Kenneth Sherman, MD, PhD | Photo/Colleen Kelley/UC Creative + Brand
“The idea of being a physician-scientist is one that I derive a great deal of satisfaction from,” explains Sherman, who sees patients from UC Medical Center, West Chester Hospital and the Cincinnati VA. “I am not just able to care for patients, but I can ask the tough questions and then use my skillset to find answers. I am able to go to leading experts in the world for collaboration to promote discovery in the field. As a result, I am able to provide the highest level of care to my patients. The University of Cincinnati has provided a venue where I can do that successfully.”
Sherman’s research focuses on viral hepatitis epidemiology, natural history, immunopathogenesis, diagnostics and treatment. HIs research has been among a number of ‘firsts’ including providing evidence during the mid-1990s that Hepatitis C (HCV) infection was a major factor in the development of liver disease in individuals living with HIV. He published the first evidence that HCV viral loads were higher in those with HIV than those with HCV alone.
Sherman applied mathematical modeling and laboratory studies to demonstrate why this might occur and how treatment would affect hepatitis C outcomes. This pioneering work played a major role in the development of the concept of ‘response-guided therapy’ tested in a multicenter, multinational clinical trial that helped lay the groundwork for FDA approval of the first direct-acting antiviral for HCV treatment. Sherman continues to publish groundbreaking work to advance our understanding and treatment of Hepatitis B, C and E.
Sherman says he was surprised and honored to be named recipient of the Distinguished Research Professor Award. “I know the University of Cincinnati only awards one of these in the STEM disciplines per year,” says Sherman. “This is a large institution with a large number of very accomplished faculty members. This was indeed an honor.”
Featured image at top of Kenneth Sherman, MD, PhD/Colleen Kelley/UC Creative + Brand.
2021 Faculty Awards
The University of Cincinnati will honor 13 awardees in a virtual ceremony at 3 p.m., Thursday, April 22. Join via WebEx.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.